Skip to main content

Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative targeted therapies for the treatment of cancer and autoimmune diseases, prominently featuring revolutionary oncology products such as revumenant (a menin inhibitor) and SNDX-6352 (axatilimab) for chronic graft-versus-host disease. The company conducts advanced clinical trials evaluating novel cancer therapeutics intended to improve patient survival and treatment response. Its core business operations encompass biopharmaceutical oncology research, clinical trial execution, drug formulation development, and commercial pharmaceutical strategy. As a commercial-stage biotechnology enterprise, the company generates revenue through pharmaceutical product sales and commercial milestone agreements. Syndax Pharmaceuticals holds a pioneering market position in targeted oncology and menin inhibition. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.

7 of the funds FundTelligence covers report a position in Syndax Pharmaceuticals.

Legal name
Syndax Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
7

Funds holding Syndax Pharmaceuticals

Loading...